CLGN Fundamental Analysis - COLLPLANT BIOTECHNOLOGIES LT

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CLGN. CLGN was compared to 558 industry peers in the Biotechnology industry. While CLGN seems to be doing ok healthwise, there are quite some concerns on its profitability. CLGN is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CLGN has reported negative net income.

CLGN had a negative operating cash flow in the past year.

CLGN had negative earnings in 4 of the past 5 years.

In the past 5 years CLGN reported 4 times negative operating cash flow.

1.2 Ratios

CLGN's Return On Assets of -80.58% is on the low side compared to the rest of the industry. CLGN is outperformed by 70.43% of its industry peers.

With a Return On Equity value of -111.85%, CLGN perfoms like the industry average, outperforming 43.01% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-80.58%
ROE	-111.85%
ROIC	N/A

ROA(3y)-51.39%

ROA(5y)-41.38%

ROE(3y)-66.85%

ROE(5y)-65.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 48.71%, CLGN is doing good in the industry, outperforming 76.34% of the companies in the same industry.

CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	48.71%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CLGN remains at a similar level compared to 1 year ago.

Compared to 5 years ago, CLGN has more shares outstanding

CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CLGN has an Altman-Z score of -7.71. This is a bad value and indicates that CLGN is not financially healthy and even has some risk of bankruptcy.

CLGN has a Altman-Z score of -7.71. This is in the lower half of the industry: CLGN underperforms 69.18% of its industry peers.

There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.71

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

CLGN has a Current Ratio of 4.48. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.48, CLGN is in line with its industry, outperforming 48.92% of the companies in the same industry.

CLGN has a Quick Ratio of 4.23. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.23, CLGN is in line with its industry, outperforming 48.92% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.48
Quick Ratio	4.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CLGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.00%.

The Revenue for CLGN has decreased by -76.72% in the past year. This is quite bad

CLGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.99% yearly.

EPS 1Y (TTM)-144%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.86%

Revenue 1Y (TTM)-76.72%

Revenue growth 3Y-67.95%

Revenue growth 5Y-25.99%

Sales Q2Q%1996.94%

3.2 Future

Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.68% on average per year.

CLGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.05% yearly.

EPS Next Y92.32%

EPS Next 2Y42.16%

EPS Next 3Y22.68%

EPS Next 5YN/A

Revenue Next Year601.14%

Revenue Next 2Y231.28%

Revenue Next 3Y73.05%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

A Price/Forward Earnings ratio of 71.57 indicates a quite expensive valuation of CLGN.

Based on the Price/Forward Earnings ratio, CLGN is valued cheaper than 88.53% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 22.30. CLGN is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	71.57

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CLGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as CLGN's earnings are expected to grow with 22.68% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.16%

EPS Next 3Y22.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CLGN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (6/4/2025, 2:24:22 PM)

2.19

-0.35 (-13.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-28 2025-05-28/bmo

Earnings (Next)07-16 2025-07-16

Inst Owners18.09%

Inst Owner Change1.14%

Ins Owners33.2%

Ins Owner ChangeN/A

Market Cap25.08M

Analysts82.86

Price Target14.28 (552.05%)

Short Float %0.03%

Short Ratio0.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-119.92%

Min EPS beat(2)-218.63%

Max EPS beat(2)-21.21%

EPS beat(4)0

Avg EPS beat(4)-76.23%

Min EPS beat(4)-218.63%

Max EPS beat(4)-21.21%

EPS beat(8)1

Avg EPS beat(8)296.42%

EPS beat(12)1

Avg EPS beat(12)161.42%

EPS beat(16)1

Avg EPS beat(16)99.24%

Revenue beat(2)0

Avg Revenue beat(2)-43.31%

Min Revenue beat(2)-62.78%

Max Revenue beat(2)-23.83%

Revenue beat(4)0

Avg Revenue beat(4)-56.16%

Min Revenue beat(4)-99.06%

Max Revenue beat(4)-23.83%

Revenue beat(8)1

Avg Revenue beat(8)-51.28%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)12%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-110.34%

EPS NY rev (1m)0%

EPS NY rev (3m)72.15%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-72.4%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-11.54%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	71.57
P/S	10.14
P/FCF	N/A
P/OCF	N/A
P/B	2.02
P/tB	2.04
EV/EBITDA	N/A

EPS(TTM)-1.22

EYN/A

EPS(NY)0.03

Fwd EY1.4%

FCF(TTM)-1.08

FCFYN/A

OCF(TTM)-1.05

OCFYN/A

SpS0.22

BVpS1.08

TBVpS1.07

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-80.58%
ROE	-111.85%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	48.71%
FCFM	N/A

ROA(3y)-51.39%

ROA(5y)-41.38%

ROE(3y)-66.85%

ROE(5y)-65.77%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	40.92%
Cap/Sales	16.59%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.48
Quick Ratio	4.23
Altman-Z	-7.71

F-Score2

WACC9.02%

ROIC/WACCN/A

Cap/Depr(3y)85.11%

Cap/Depr(5y)108.12%

Cap/Sales(3y)180.83%

Cap/Sales(5y)112.23%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-144%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.86%

EPS Next Y92.32%

EPS Next 2Y42.16%

EPS Next 3Y22.68%

EPS Next 5YN/A

Revenue 1Y (TTM)-76.72%

Revenue growth 3Y-67.95%

Revenue growth 5Y-25.99%

Sales Q2Q%1996.94%

Revenue Next Year601.14%

Revenue Next 2Y231.28%

Revenue Next 3Y73.05%

Revenue Next 5YN/A

EBIT growth 1Y-75.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y17.82%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y13.87%

OCF growth 3YN/A

OCF growth 5YN/A

COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens